Sprouty-2 Regulation of Signaling in Asthma

Sprouty-2 哮喘信号传导的调节

基本信息

  • 批准号:
    9081472
  • 负责人:
  • 金额:
    $ 39.63万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-07-15 至 2018-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Asthma is a chronic inflammatory disease of the airways where T cells manifest a biased Th2/Th17 differentiation and a hyperactive phenotype. The latter is associated with sustained intracellular signaling. Signaling processes are usually transient due to negative homeostatic regulation. There is a knowledge gap in our understanding of mechanisms that induce sustained signaling. We propose to delineate the mechanism of induction of sustained signaling in T cells from asthma. We have reported that the signaling molecule sprouty 2 (spry 2) plays an essential role in establishing a self-sustained signaling mechanism for ERK1/2. To address this further we have generated CD4 targeted spry 2 knockout mice. Spry2-/- T cells have increased Cbl-b and decreased Nedd4. The foregoing ubiquitin ligases antagonistically regulate TCR ubiquitylation, endocytosis, degradation and thereby, control TCR signaling output. As a consequence of these receptor proximal abnormalities spry2-/-T cells have impaired signaling and proliferation. These impairments become more pronounced following CD28 engagement. Spry2-/- T cells have impaired Th2/Th17 differentiation. They are unable to mount airway inflammation, hyperreactivity and remodeling in a mouse model of asthma. Based upon these preliminary results we hypothesize that spry 2 amplifies and prolongs T cell signaling by forming a tripartite regulatory network where spry 2 and Nedd4 antagonize the signal terminating action of Cbl-b. Spry2- driven amplification and sustenance of signaling is important for co-stimulation, Th2/Th17 differentiation and development of asthma. Under specific aim 1 we will examine the role of spry 2 in generating sustained signaling in T cells. We will define the scope of CD3- and especially CD28-induced signaling pathways that are regulated by spry 2. We will examine the contribution of Cbl-b and Nedd4 to the spry2 knockout phenotype. Specific aim 2 will study the importance of spry 2 for Th2 and Th17 cell differentiation in vitro and in vivo in spry2-/- mice. We will delineae the signaling mechanism by which spry 2 regulates Th2/Th17 differentiation. Under specific aim 3 we will delineate the role of spry 2 in inducing and sustaining inflammation in a mouse model of chronic asthma. We will examine if Cbl-b knockout reverses the spry2 knockout phenotype. Under specific aim 4 we will study the expression of spry 2 in CD4 T cells from asthmatic patients and examine its contribution to the hyperactive T cell phenotype and biased differentiation in asthma. These studies are important because they have uncovered a hitherto unknown regulatory network involving spry2, Cbl-b and Nedd4, which controls Th2/Th17 differentiation and development of asthma.
描述(由申请人提供):哮喘是气道的慢性炎症性疾病,其中T细胞表现出偏向的Th 2/Th 17分化和过度活跃的表型。后者与持续的细胞内信号传导有关。由于负稳态调节,信号传导过程通常是短暂的。我们对诱导持续信号传导的机制的理解存在知识缺口。我们建议描绘的机制,诱导持续的信号在T细胞哮喘。我们已经报道了信号分子sprouty 2(spry 2)在建立ERK 1/2的自我维持信号机制中起着至关重要的作用。为了进一步解决这个问题,我们已经产生了CD 4靶向的spry 2敲除小鼠。Spry 2-/- T细胞具有增加的Cbl-b和减少的Nedd 4。前述泛素连接酶拮抗性地调节TCR泛素化、内吞作用、降解,从而控制TCR信号传导输出。作为这些受体近端异常的结果,spry 2-/-T细胞具有受损的信号传导和增殖。这些损伤在CD 28参与后变得更加明显。Spry 2-/- T细胞具有受损的Th 2/Th 17分化。他们不能在哮喘小鼠模型中增加气道炎症、高反应性和重塑。基于这些初步结果,我们假设spry 2通过形成三方调节网络来放大和抑制T细胞信号传导,其中spry 2和Nedd 4拮抗Cbl-b的信号终止作用。Spry 2驱动的信号放大和维持对于共刺激、Th 2/Th 17分化和哮喘的发展是重要的。在具体目标1下,我们将研究spry 2在T细胞中产生持续信号传导的作用。我们将定义由spry 2调节的CD 3-尤其是CD 28-诱导的信号通路的范围。我们将检查Cbl-b和Nedd 4对spry 2敲除表型的贡献。具体目标2将研究spry 2对spry 2-/-小鼠体外和体内Th 2和Th 17细胞分化的重要性。我们将阐明spry 2调节Th 2/Th 17分化的信号转导机制。在具体目标3中,我们将描述spry 2在慢性哮喘小鼠模型中诱导和维持炎症的作用。我们将检查Cbl-b敲除是否逆转spry 2敲除表型。在具体目标4下,我们将研究哮喘患者CD 4 T细胞中spry 2的表达,并检查其对哮喘中过度活化T细胞表型和偏向分化的贡献。这些研究很重要,因为它们揭示了一个迄今未知的涉及spry 2、Cbl-b和Nedd 4的调控网络,该网络控制着Th 2/Th 17分化和哮喘的发展。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Rafeul Alam其他文献

Rafeul Alam的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Rafeul Alam', 18)}}的其他基金

DNA induction of neutrophilic asthma
DNA诱导中性粒细胞性哮喘
  • 批准号:
    10490869
  • 财政年份:
    2021
  • 资助金额:
    $ 39.63万
  • 项目类别:
DNA induction of neutrophilic asthma
DNA诱导中性粒细胞性哮喘
  • 批准号:
    10686177
  • 财政年份:
    2021
  • 资助金额:
    $ 39.63万
  • 项目类别:
DNA induction of neutrophilic asthma
DNA诱导中性粒细胞性哮喘
  • 批准号:
    10343318
  • 财政年份:
    2021
  • 资助金额:
    $ 39.63万
  • 项目类别:
ILC2 memory in asthma
哮喘中的 ILC2 记忆
  • 批准号:
    10685256
  • 财政年份:
    2020
  • 资助金额:
    $ 39.63万
  • 项目类别:
ILC2 memory in asthma
哮喘中的 ILC2 记忆
  • 批准号:
    10267732
  • 财政年份:
    2020
  • 资助金额:
    $ 39.63万
  • 项目类别:
ILC2 memory in asthma
哮喘中的 ILC2 记忆
  • 批准号:
    10458013
  • 财政年份:
    2020
  • 资助金额:
    $ 39.63万
  • 项目类别:
Steroid resistance of airway ILC2s
气道 ILC2 的类固醇抵抗
  • 批准号:
    9914206
  • 财政年份:
    2018
  • 资助金额:
    $ 39.63万
  • 项目类别:
Steroid resistance of airway ILC2s
气道 ILC2 的类固醇抵抗
  • 批准号:
    10400040
  • 财政年份:
    2018
  • 资助金额:
    $ 39.63万
  • 项目类别:
Airway Th2Th17 Cells in Refractory Asthma
难治性哮喘中的气道 Th2Th17 细胞
  • 批准号:
    9029107
  • 财政年份:
    2016
  • 资助金额:
    $ 39.63万
  • 项目类别:
Sprouty-2 Regulation of Signaling in Asthma
Sprouty-2 哮喘信号传导的调节
  • 批准号:
    8892055
  • 财政年份:
    2014
  • 资助金额:
    $ 39.63万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了